Last updated: 2026-09-09 04:51:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BioLife Solutions Inc. (BLFS) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $35.38, with a market capitalization of $1.72B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.86 to $38.10. This page covers its latest market performance, valuation, price trends and company information.
$1.72B | |
$35.03 | |
$60.67 | |
$1.43 | |
$35.25 | |
746.00K | |
1.10M | |
-- | |
$38.10 | |
$17.86 | |
-- | |
-- |
BioLife Solutions Inc. (BLFS) last closed at $35.25 as of 2026-09-08 23:31:00, unchanged from the previous close of $35.25.
During the latest regular trading session, BLFS traded between $1.43 and $60.67, with a volume of 746.00K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, BioLife Solutions Inc. (BLFS) moved from $37.20 to $35.38, representing a decline of 4.88% ($1.82).
The stock traded between $34.58 and $37.39 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 925.74 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 86.6%
BLFS is currently trading at $35.38, placing it 86.6% of the way from its 52-week low of $17.86 to its 52-week high of $38.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 155 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioLife Solutions Inc. (BLFS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.